Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on sleep in brain health

LIVE: Thursday 2nd May 2024, 18:00-19:30 (CEST)

Quality sleep is essential for health. But what happens to our brains when sleep patterns are disturbed? Join our experts to explore the interplay between sleep disruption and neurological diseases, and the questions that you need to be asking your patients to help you prevent the harmful effects of sleep deprivation.
ADVANCED SEARCH
Log in
Top
Neurological Sciences
Published in: Neurological Sciences 2/2020

01-12-2020 | Migraine | BRIEF COMMUNICATION

Erenumab in 159 high frequency and chronic migraine patients: real-life results from the Bologna Headache Center

Authors: Eleonora Matteo, Valentina Favoni, Alessia Pascazio, Umberto Pensato, Matteo Benini, Gian Maria Asioli, Elena Merli, Calogero Calabrò, Pietro Cortelli, Giulia Pierangeli, Sabina Cevoli

Published in: Neurological Sciences | Special Issue 2/2020

Login to get access

Excerpt

Migraine is one of the most prevalent and disabling conditions worldwide. Treatment of migraine can involve both acute and preventive interventions. Patients with frequent headache may require both approaches. Acute treatment is aimed at aborting the headache attack, whereas preventive treatment is geared toward reducing the frequency and severity of attacks. Monoclonal antibodies against CGRP (mAbs) are a novel therapeutic preventive option for patients with migraine [1]. Among mAbs, erenumab selectively targets the CGRP receptor. Randomized controlled trials have proven efficacy and safety of erenumab as preventive treatment for both episodic and chronic migraine (CM); however, real-life studies are still needed to confirm these results in everyday clinical practice. …
Literature
1.
Sacco S, Bendtsen L, Ashina M, Reuter U, Terwindt G, Mitsikostas D, Martelletti P (2019) European headache federation guideline on the use of monoclonal antibodies acting on the calcitonin gene related peptide or its receptor for migraine prevention. J Headache Pain 20:6CrossRef
2.
Barbanti P, Aurilia C, Egeo G, Fofi L (2019) Erenumab: from scientific evidence to clinical practice—the first Italian real-life data. Neurol Sci 40(1):177–179CrossRef
3.
Ornello R, Casalena A, Frattale I et al (2020) Real-life data on the efficacy and safety of erenumab in the Abruzzo region, central Italy. J Headache Pain 21(1)
Metadata
Title
Erenumab in 159 high frequency and chronic migraine patients: real-life results from the Bologna Headache Center
Authors
Eleonora Matteo
Valentina Favoni
Alessia Pascazio
Umberto Pensato
Matteo Benini
Gian Maria Asioli
Elena Merli
Calogero Calabrò
Pietro Cortelli
Giulia Pierangeli
Sabina Cevoli
Publication date
01-12-2020
Publisher
Springer International Publishing
Published in
Neurological Sciences / Issue Special Issue 2/2020
Print ISSN: 1590-1874
Electronic ISSN: 1590-3478
DOI
https://doi.org/10.1007/s10072-020-04667-0

Other articles of this Special Issue 2/2020

Neurological Sciences 2/2020 Go to the issue

Brief Communication

Headache relevance in outpatient activity during Covid-19 pandemic

BRIEF COMMUNICATION

A longitudinal clinical and MRI evaluation of the treatment with erenumab

BRIEF COMMUNICATION

Appropriateness of magnetic resonance angiography in the evaluation of migraine patients

BRIEF COMMUNICATION

Exploring new strategy in erenumab therapy for migraine patients

THERAPEUTICAL SCENARIOS IN HEADACHES

Moving closer to the ideal migraine acute treatment

BRIEF COMMUNICATION

Anti-CGRP monoclonal antibodies in cluster headache: what can we learn from recent clinical trials